Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Recommendation of “Hold” by Analysts

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have earned a consensus recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $38.3333.

PHAR has been the topic of several recent analyst reports. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Weiss Ratings cut Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen cut Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Canaccord Genuity Group initiated coverage on Pharming Group in a research note on Friday, April 10th. They set a “buy” rating and a $37.00 price objective on the stock. Finally, Oppenheimer reiterated an “outperform” rating and set a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th.

Pharming Group Price Performance

Pharming Group stock opened at $12.87 on Wednesday. The company has a quick ratio of 2.06, a current ratio of 2.63 and a debt-to-equity ratio of 0.35. Pharming Group has a 12-month low of $9.54 and a 12-month high of $21.34. The stock has a market cap of $908.88 million, a price-to-earnings ratio of 80.44 and a beta of -0.04. The business’s 50-day simple moving average is $14.11 and its 200 day simple moving average is $15.98.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, May 7th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.The company had revenue of $72.45 million for the quarter, compared to the consensus estimate of $92.06 million. As a group, research analysts anticipate that Pharming Group will post 0.6 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

Several institutional investors and hedge funds have recently modified their holdings of PHAR. EverSource Wealth Advisors LLC acquired a new position in Pharming Group in the 2nd quarter valued at $32,000. SmartHarvest Portfolios LLC bought a new stake in shares of Pharming Group during the 4th quarter worth $224,000. Millennium Management LLC bought a new stake in shares of Pharming Group during the 4th quarter worth $360,000. Finally, NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the last quarter. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.